Optic Disc Edema, Globe Flattening, Choroidal Folds, and Hyperopic Shifts Observed in Astronauts after Long-duration Space Flight

Thomas H. Mader, MD,1 C. Robert Gibson, OD,2 Anastas F. Pass, OD, JD,3 Larry A. Kramer, MD,4 Andrew G. Lee, MD,5 Jennifer Fogarty, PhD,6 William J. Tarver, MD,6 Joseph P. Dervay, MD,6 Douglas R. Hamilton, MD, PhD,7 Ashot Sargsyan, MD,7 John L. Phillips, PhD,8 Duc Tran, DO,2 William Lipsky, MD,2 Jung Choi, OD,2 Claudia Stern, MD, PhD,9 Raffi Kuyumjian, MD,10 James D. Polk, DO6

Purpose: To describe the history, clinical findings, and possible etiologies of ophthalmic findings discovered in 7 astronauts after long-duration space flight, and document vision changes in approximately 300 additional astronauts.

Design: Retrospective, observational examination of ophthalmic findings in 7 astronauts and analysis of postflight questionnaires regarding in-flight vision changes in approximately 300 additional astronauts.

Participants: Seven astronauts with ophthalmic anomalies upon return from long-duration space missions to the International Space Station and 300 additional astronauts who completed postflight questionnaires regarding in-flight vision changes.

Methods: Before and after long-duration space flight, all 7 subjects underwent complete eye examinations, including cycloplegic and/or manifest refraction and fundus photography. Six underwent postmission optical coherence tomography (OCT) and magnetic resonance imaging (MRI); 4 had lumbar punctures (LP). Approximately 300 astronauts were queried regarding visual changes during space missions.

Main Outcome Measures: Refractive change, fundus photograph examination, retina OCT, orbital MRI, LP opening pressures, and examination of visual acuity data.

Results: After 6 months of space flight, 7 astronauts had ophthalmic findings, consisting of disc edema in 5, globe flattening in 5, choroidal folds in 5, cotton wool spots (CWS) in 3, nerve fiber layer thickening by OCT in 6, and decreased near vision in 6 astronauts. Five of 7 with near vision complaints had a hyperopic shift ≥ +0.50 diopters (D) between pre/postmission spherical equivalent refraction in 1 or both eyes (range, +0.50 to +1.75 D). These 5 showed globe flattening on MRI. Lumbar punctures performed in the 4 with disc edema documented opening pressures of 22, 21, 28, and 28.5 cm H2O performed 60, 19, 12, and 57 days postmission, respectively. The 300 postflight questionnaires documented that approximately 29% and 60% of astronauts on short and long-duration missions, respectively, experienced a degradation in distant and near visual acuity. Some of these vision changes remain unresolved years after flight.

Conclusions: We hypothesize that the optic nerve and ocular changes we describe may result from cephalad fluid shifts brought about by prolonged microgravity exposure. The findings we report may represent parts of a spectrum of ocular and cerebral responses to extended microgravity exposure.

Financial Disclosure(s): The authors have no proprietary or commercial interest in any of the materials discussed in this article. Ophthalmology 2011;xx:xxx © 2011 by the American Academy of Ophthalmology.
CSF = cerebral spinal fluid; MRI = magnetic resonance imaging; NFL = retinal nerve fiber layer; OCT = optical coherence tomography; OD = right; Disc edema was graded with the modified Frisén scale.

our knowledge, this is the first published report documenting ophthalmic anomalies in astronauts or cosmonauts during or after space flight.

Subjects and Methods

A postflight survey of approximately 300 astronauts, some of whom were repeat flyers, revealed that vision changes were commonly observed during and after long-duration space missions. Since 1989, as part of the postflight eye examination, astronauts were queried as to whether they perceived a subjective improvement or degradation in distant or near vision (none, mild, moderate, or severe) during their short- and long-duration missions. Prompted by persistent reports of vision changes, NASA began a stepwise operational process to determine the etiology. Several ophthalmic procedures were initiated on astronauts, including dilated fundus examinations with binocular ophthalmoscopy, cycloplegic refraction, optical coherence tomography (OCT), magnetic resonance imaging (MRI) of orbits, and fundus photos of astronauts before and after space missions.

Space flight causes bone loss. As a countermeasure, it is recommended that all astronauts take 800 international units (IU) of vitamin D supplements daily during short- and long-duration space flights. Unless otherwise stated, the past medical history of all 7 astronauts was negative for systemic hypertension, connective tissue disorders, iron deficiency, diabetes mellitus, or renal disease. Again, unless stated otherwise, none of our subjects had ever used any medication that could produce increased intracranial pressure (ICP); (e.g., vitamin A, tetracycline, corticosteroids, or nalidixic acid.)

The NASA Space Medicine Division approves of the use of this routinely acquired and not attributable data to be used in this manner. These data are acquired under occupational surveillance and their use in this article is permitted under governance 10 Health Information Management System.

Results

After approximately 6 months of continuous orbital flight, 7 astronauts (all male; age 50.2 ± 4.2 years) were documented to have findings as summarized in Table 1. Table 2 is a summary of data from postflight questionnaires completed by approximately 300 astronauts from 1989 to 2009.

Table 2. Reported In-Flight Subjective Visual Changes and Postflight Refraction Changes of National Aeronautics and Space Administration Astronauts (Not Including International Partners) from 1989 to 2009

<table>
<thead>
<tr>
<th>Description</th>
<th>Shuttle % (n)</th>
<th>ISS-Long Duration % (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decreased DVA</td>
<td>581 (587)</td>
<td>44 (4)</td>
</tr>
<tr>
<td>None</td>
<td>93.5 (543)</td>
<td>88.1 (39)</td>
</tr>
<tr>
<td>Mild</td>
<td>5.7 (33)</td>
<td>2.4 (1)</td>
</tr>
<tr>
<td>Moderate</td>
<td>0.9 (5)</td>
<td>4.8 (2)</td>
</tr>
<tr>
<td>Severe</td>
<td>0 (0)</td>
<td>4.8 (2)</td>
</tr>
<tr>
<td>Decreased NVA</td>
<td>581 (587)</td>
<td>44 (4)</td>
</tr>
<tr>
<td>None</td>
<td>76.7 (448)</td>
<td>52.3 (23)</td>
</tr>
<tr>
<td>Mild</td>
<td>17.6 (103)</td>
<td>13.6 (6)</td>
</tr>
<tr>
<td>Moderate</td>
<td>5.5 (32)</td>
<td>27.3 (12)</td>
</tr>
<tr>
<td>Severe</td>
<td>0.2 (1)</td>
<td>6.8 (3)</td>
</tr>
<tr>
<td>Refraction change</td>
<td>587 (587)</td>
<td>44 (4)</td>
</tr>
<tr>
<td>None</td>
<td>88.9 (522)</td>
<td>65.9 (29)</td>
</tr>
<tr>
<td>Mild</td>
<td>9.2 (54)</td>
<td>25.0 (11)</td>
</tr>
<tr>
<td>Moderate</td>
<td>1.9 (11)</td>
<td>2.3 (1)</td>
</tr>
<tr>
<td>Severe</td>
<td>0 (0)</td>
<td>6.8 (3)</td>
</tr>
</tbody>
</table>

DVA = distance visual acuity; ISS = International Space Station; NVA = near visual acuity.
Source: Lifetime Surveillance of Astronaut Health (LSAH) Program, NASA Johnson Space Center.
astronauts after their short- and long-duration space missions. Approximately 23% of the short-duration and 48% of the long-duration mission astronauts complained of near vision difficulties.

**Case Reports**

**Case 1**

This astronaut’s preflight manifest refraction at 90 days before launch was: right eye, −1.50 sphere and left eye, −2.25 −0.25×135, with a +1.50 add. He was correctable to 20/20 in each eye and his dilated eye examination and fundus photos were normal. The only medication he used was promethazine for space adaptation syndrome. He noticed a marked decrease in near visual acuity starting about 6 weeks into the mission that persisted without progression for the remainder of the flight. At no time did he report headaches, transient visual obscurations, pulsatile tinnitus, or diplopia. Carbon dioxide levels were at normal operating levels during the mission, and he was not exposed to any toxic substances.

Nineteen days after return to Earth, his visual acuity was correctable in each eye to 20/15. He had +2.25 bifocal add in both lenses. His dilated fundus examination was normal and documented with preflight fundus photos. During the mission, he took a multivitamin daily, potassium citrate (part of an experiment), and zolpidem occasionally for sleep induction.

After his return to Earth, a fundus examination was performed, which documented mild bilateral nasal optic disc edema (grade 1, Frisén scale), right greater than left, and choroidal folds (Fig 1, available online at [http://aaojournal.org](http://aaojournal.org)). The acquired choroidal folds gradually improved, which documented mild bilateral nasal optic disc edema (grade 1, Frisén scale), right greater than left, and choroidal folds (Fig 1, available online at [http://aaojournal.org](http://aaojournal.org)). Fluorescein angiography confirmed the choroidal folds but showed no other abnormalities. Magnetic resonance angiography and magnetic resonance venogram were normal. The OCT confirmed the increased nerve fiber layer (NFL) thickening consistent with optic disc edema nasally and demonstrated a normal macula. An MRI of the brain and orbits with and without gadolinium contrast, performed 23 days after return to Earth clearly while looking through the lower portion of his glasses. Approximately 3 months into the mission, he noted that he could now only see the Earth clearly without glasses. Approximately 3 months into the mission, he noted that he could now only see the Earth clearly without glasses.

**Case 2**

This astronaut’s manifest refraction 120 days before the mission was +0.75 sphere on the right and +0.75 −0.25×165 on the left; his visual acuity was correctable in each eye to 20/15. He had a +2.25 bifocal add in both lenses. His dilated fundus examination was normal and documented with preflight fundus photos. During the mission, he took a multivitamin daily, potassium citrate (part of an experiment), and zolpidem occasionally for sleep induction.

During the first 2 months in orbit, he had no visual complaints and could see the Earth clearly without glasses. Approximately 3 months into the mission, he noted that he could now only see the Earth clearly while looking through the lower portion of his progressive reading glasses. This change persisted for the remainder of the mission without noticeable improvement or progression. He complained of no transient visual obscurations, headaches, diplopia, pulsatile tinnitus, or vision changes during eye movement. Carbon dioxide, cabin pressure, and oxygen were at normal operating levels during the mission, and he was not exposed to any toxic substances.

Upon return to Earth, the vision disturbances observed during microgravity continued. Twenty-one days after the mission, his visual acuity was correctable to 20/20 with a manifest refraction of +2.00 sphere on the right and +2.00 −0.50×140 on the left. Over the next several months, he noted a gradual but incomplete improvement in vision. His refraction 232 days postflight was +1.50 sphere on the right and +1.50 −0.25×170 on the left. He never at any time experienced losses in subjective best-corrected visual acuity, stereopsis, or color vision. Twenty-one days after his return to Earth, a fundus examination was performed, which documented mild bilateral nasal optic disc edema (grade 1, Frisén scale), right greater than left, and choroidal folds (Fig 2, available online at [http://aaojournal.org](http://aaojournal.org)). Fluorescein angiography confirmed the choroidal folds but showed no other abnormalities. Magnetic resonance angiography and magnetic resonance venogram were normal. The OCT confirmed the increased nerve fiber layer (NFL) thickening consistent with optic disc edema nasally and demonstrated a normal macula. An MRI of the brain and orbits with and without gadolinium contrast, performed 23 days after return to Earth.
return, documented mildly dilated ON sheaths and flattening of the posterior globes bilaterally. A CWS was present in the left eye 1 and 1 half disc diameters inferior temporal to the disc and just inside the inferior arcades. Two months after return to Earth, a LP documented a borderline opening pressure of 22 cm H$_2$O with normal cerebral spinal fluid (CSF) composition.

**Case 3**

Preflight cycloplegic refraction was $-0.50$ sphere in the right eye and $-0.25$ sphere in the left eye, and correctable in each eye to 20/15. His past medical history included mild systemic hypertension controlled with lisinopril (10 mg) and dyslipidemia, well-controlled on atorvastatin (10 mg). During the mission, he also took promethazine for 2 days to treat symptoms of space adaptation syndrome, and a multivitamin (Centrum Silver, Pfizer, New York, New York), but no additional vitamin A analogs. He reported no changes in visual acuity during the mission with no complaints of headaches, transient visual obscurations, diplopia, or pulsatile tinnitus. Carbon dioxide and oxygen levels were at acceptable levels during the mission, and he had no toxic exposures. No ocular issues were reported by the astronaut at landing.

Three days after return to Earth, he was correctable to 20/20 both eyes with a cycloplegic refraction of plano in each eye. Fundus examination revealed bilateral, asymmetrical disc edema (right eye, grade 3; left eye, grade 1; Fig 3). There was no evidence of choroidal folds or CWS. A small hemorrhage was observed inferior to the optic disc in the right eye. At 10 days postlanding, an MRI of the brain and orbits was normal except for ON thickening in the right eye greater than the left eye (Fig 4; available online at [http://aaojournal.org](http://aaojournal.org)). There was no posterior globe flattening. A magnetic resonance venogram showed no evidence for cerebral venous sinus thrombosis. On OCT, there was marked NFL thickening (right eye more than the left eye), consistent with optic disc edema (Fig 5; available online at [http://aaojournal.org](http://aaojournal.org)). At 19 days after return to Earth, an LP documented a mildly elevated opening pressure of 21 cm H$_2$O with normal CSF composition.

**Case 4**

Preflight eye examination revealed a cycloplegic refraction of $-0.75$ to 0.50×100 on the right and plano $-0.50$×090 on the left, correctable in each eye to 20/15. He had a reading add of $+2.00$ both eyes. His preflight dilated eye examination and fundus photos were normal. During the mission, he used a topical corticosteroid and oral ketoconazole for a facial rash and promethazine for 1 day to treat symptoms of space adaptation syndrome. During the mission, this astronaut took a 6-day tapering dose of methylprednisolone followed by prednisone 40 mg/d for 1 week to treat an allergic skin condition.

Approximately 6 to 8 weeks into the mission, he reported a progressive decrease in near visual acuity in his right eye, followed
by a mild, “vertical football”–shaped scotoma located 15° to 30° into his right temporal field of vision. The scotoma seemed to be fixed and translucent, and was stable for the remainder of the mission. He never complained of transient visual obscurations, headaches, diplopia, pulsatile tinnitus, or vision changes during eye movement. International Space Station (ISS) cabin pressure, carbon dioxide, and oxygen levels were reported to be at normal operating levels during the mission. During the mission, one of his fellow astronauts also complained of decreased near visual acuity (case 5). Five months into the mission, a video funduscopic imaging system was used to obtain retinal and ON images that were downlinked to NASA personnel for ophthalmologic consultation. These images allowed experts on the ground to diagnose mild optic disc edema in the right eye (Fig 6). The temporal location and shape of the reported scotoma was thought to be consistent with disc edema (i.e., enlarged blind spot).

His vision changes persisted upon return to Earth. Ten days postflight, his visual acuity was correctable to 20/15 with a cycloplegic refraction of \( +0.75 \) to \( -1.25 \) on the right and to \( +0.75 \) to \( -0.50 \times 090 \) on the left. He never experienced losses in subjective best-corrected acuity, color vision, or stereopsis. Fundus examination revealed mild, nasal disc edema (grade 1, Frisén scale) of the right eye with choroidal folds extending from the disc into the macula (Fig 6). On OCT, optic disc edema and choroidal folds were confirmed (Fig 7; available online at http://aaojournal.org). An MRI of the brain and orbits performed 30 days postflight documented severely dilated ON sheaths (right greater than left), flattening of the posterior globes (right greater than left), and thickened tortuous ONs (Fig 8). An intracranial magnetic resonance venogram and magnetic resonance angiography subsequently obtained showed no abnormalities. Fifty-seven days after return to Earth, an LP documented an elevated opening pressure of 28.5 cm H\(_2\)O with normal CSF composition.

**Case 5**

A preflight eye examination revealed a cycloplegic refraction of \(-5.75\) to \(1.25 \times 010\) on the right, and \(-5.00\) to \(1.50 \times 180\) on the left, correctable in each eye to 20/20. His reading add was \(+1.75\) both eyes. Dilated eye examination and fundus photos were normal. During the mission, he took promethazine for a few days to treat symptoms of space adaptation syndrome. Three weeks after launch, he reported a moderate decrease in near visual acuity, right eye greater than left, which persisted for the remainder of the mission without change. He never complained of headaches, transient visual obscurations, diplopia, pulsatile tinnitus, or other vision changes. Carbon dioxide, oxygen, and ISS cabin pressure were at acceptable levels during the mission. One fellow crewmember complained of visual changes (case 4).

Upon return to Earth, he noted persistence of the vision changes he observed in space. Postflight visual acuity was correctable to 20/20 both eyes with a manifest and cycloplegic refraction of \(-5.00\) to \(1.50 \times 015\) on the right and \(-4.75\) to \(1.75 \times 170\) on the left and a reading add of \(+2.25\) both eyes. He never experienced losses in subjective best-corrected acuity, color vision, or stereopsis. His fundus examination was normal with no evidence of disc edema.
Preflight cycloplegic refraction was +1.50 sphere on the right and +0.75 sphere on the left. He never experienced losses in subjective best-corrected acuity, color vision, or stereopsis. Fundus examination and OCT performed at this time documented mild disc edema (right eye, grade 1) and a CWS in the left eye 2 disc diameters superior temporal to the disc, just inside the superior arcade. Although no choroidal folds were visible by ophthalmoscopy in either eye, mild choroidal folds were noted in the right eye by OCT (Fig 11; available online at http://aaojournal.org). An LP was not performed.

Case 7

Preflight cycloplegic refraction was +1.25 sphere both eyes, correctable in each eye to 20/15 with a reading add of +1.75. His preflight dilated eye examination and fundus photos were normal. During the mission, he took promethazine 25 mg by mouth on day 1 of the mission and 12.5 mg on day 2 to treat symptoms of space adaptation syndrome. While in orbit, he took atorvastatin 40 mg every day, vitamin D 50 000 IU/month, and 800 mg ibuprofen as needed. Approximately 2 months into the mission he reported a progressive decrease in his near and far acuity in both eyes, which persisted for the remainder of the mission. At approximately 3 to 4 months into the 6-month mission, he noticed that his normal “Earth” prescription progressive glasses were no longer strong enough for near tasks at which time he began using his stronger “Space Anticipation Glasses” (+1.25 D more plus). He never complained of transient visual obscurations, headaches, diplopia, pulsatile tinnitus, or vision changes during eye movement. The ISS cabin pressure, carbon dioxide, and oxygen levels were reported to be at normal operating levels during the mission. He was not exposed to any toxic substances.

Three days after his return to Earth, his visual acuity was correctable to 20/20 both eyes with a cycloplegic refraction of +2.75 sphere on the right, and +2.50 sphere on the left. He never experienced losses in subjective best-corrected acuity, color vision, or stereopsis. A fundus examination revealed mild bilateral optic disc edema (grade 1), and choroidal folds (Fig 12; available online at http://aaojournal.org; Fig 13 and 14). On OCT, optic disc edema and chorioretinal folds were confirmed (Fig 15). An MRI of the brain and orbits performed 6 days postflight documented bilateral flattening of the posterior globes, distended ON sheaths, and papilledema. Twelve days after return to Earth, LP documented an elevated opening pressure of 28 cm H₂O with normal CSF composition. A mild degradation in uncorrected near visual acuity and a mild hypopicopic shift was documented on this astronaut after a previous short-duration Space Shuttle mission several years before his long-duration mission. His post–Space Shuttle, short-duration flight eye examination was normal with no evidence of disc edema or choroidal folds. At that time, MRI and OCT were not performed postflight. His preflight long-duration OCT raster scans showed what could be evidence of residual choroidal folds from his prior short-duration mission (Fig 15).

Discussion

In this report, we have described the development of ophthalmic findings in astronauts after long-duration space flight. Although the etiology of these findings remains unknown we propose that one of several mechanisms, or a combination thereof, may best explain our observations. The first possible explanation is that the findings we describe resulted from increased ICP brought about by prolonged microgravity exposure. Numerous authors have de-
scribed optic disc edema, globe flattening, choroidal folds, and a hyperopic shift in a terrestrial environment, which were thought to be part of the well-defined but still idiopathic syndrome of idiopathic intracranial hypertension (IIH). Several reports have described the ultrasonography, OCT, MRI and computed tomography findings in IIH that include flattening of the posterior globe and enlargement of the subarachnoid space (SAS) around the ON sheath. The elevated subarachnoid pressure, caused by intracranial hypertension, is thought to be directly transmitted from the intracranial compartment to the intraorbital compartment through the perioptic SAS. This results in distension of the ON sheaths and stasis of axoplasmic flow resulting in axonal swelling and visible disc edema. Elevated intrasheath pressure is thought to cause the subarachnoid compartment to exert an anterior force that indents the posterior sclera resulting in posterior globe flattening, redundancy and folding of the choroid, and axial shortening. The disc edema, posterior globe flattening, choroidal folds, and hyperopic shift seen in cases 2, 4, 6, and 7 seem to be consistent with this description. Case 4 is particularly demonstrative (Fig 8). Additionally, we measured elevated LP opening pressures of 28.5 and 28 cm H$_2$O at 57 days and 12 days, respectively, after returning to Earth. Although these opening pressures were only mildly elevated, they could represent the downslope of a pressure spike that may have existed during microgravity exposure.

The specific mechanism of an IIH-like syndrome in extended microgravity may involve a rise in cephalad venous pressure brought about by microgravity fluid shifts. Head-down and microgravity studies document that cerebral arterial diameter and blood flow velocity are autoregulated and do not change significantly during space flight. In contrast, microgravity fluid shifts are well-documented to cause jugular vein distension, which suggests that cerebral venous congestion may be present in the microgravity environment. The classical view of ICP regulation assumes that CSF is largely produced in the choroid plexus and drainage depends on the pressure difference between the CSF and the venous system. In this scenario, venous stasis in the head and neck, produced by cephalad fluid shifts, may cause an impairment of CSF outflow as well as cerebral venous congestion, both of which would presumably lead to a rise in ICP. An alternate hypothesis suggests that CSF formation and absorption are due to a balance between hyperosmolar plasma in high pressure capillaries, and the subsequent absorption of the formed hypo-osmolar interstitial fluid by the low-pressure venules that are in anatomic proximity to the high-pressure capillaries. According to this hypothesis, CSF is permanently produced and absorbed in the entire CSF system. If this is true, the microgravity environment may cause interstitial venous stasis at the level of low pressure CSF venules and a subsequent decrease in the osmotic drive toward absorption,
resulting in increased ICP. Regardless of the specific mechanism, perhaps in some anatomically predisposed astronauts, increased venous congestion causes a rise in CSF pressure of sufficient magnitude to produce the changes described.

There are significant arguments against increased ICP being the sole etiology in the cases we describe. Although we documented only 2 cases with a clearly elevated LP opening pressure, our findings in 2 additional patients of disc edema, ON sheath thickening, and posterior globe flattening are suggestive of a rise in ICP. However, several factors may speak against a rise in ICP as a universal cause of all such findings in the astronaut population. First, this
supposition is largely based on the similarity of our astronaut’s fundi to those of IIH patients observed in a terrestrial setting. However, the disease process of these IIH patients arose on Earth, where microgravity and cephalad fluid shifts played no role in the creation of disc edema, so the specific etiology cannot be determined on the basis of fundus examination alone. Second, none of our patients with disc edema, globe flattening, choroidal folds, or hyperopic shifts presented with chronic headaches, diplopia, transient visual obscurations, pulse-synchronous tinnitus, or other clinical symptoms suggestive of elevated ICP. Headache is experienced by >90% of IIH patients, transient visual obscurations in 68%, and VIth nerve palsy in 30%. This consistent lack of symptoms would be unusual with an ICP of sufficient magnitude to produce clinically recognizable disc edema. Third, because no LP was performed in the ISS during the missions, we have no direct confirmatory evidence that a rise in ICP ever existed during space flight. Fourth, the prominent degree of globe flattening, disc edema, widened ON sheaths, and choroidal folds documented in these astronauts are clearly out of proportion to the relatively unimpressive ICP measurements. Therefore, etiologies other than a rise in ICP should be considered.

The second possible explanation of our findings is that the ON head edema is the result of localized events occurring at the level of the intraorbital ON without a rise in CSF pressure. It has generally been assumed that there is homogeneity of pressure and CSF component concentrations throughout the SAS of the ONs. However, impaired exchange of fluid between the intracranial CSF and that in the SAS of the ON has been proposed as a possible mechanism to explain persistent papilledema and visual loss in patients with IIH despite a functioning lumbo-peritoneal shunt. As mentioned, a new hypothesis suggests that CSF is permanently produced and absorbed in the entire CSF system as a consequence of filtration and reabsorption of water volume through the capillary walls into the surrounding brain tissue. This implies that the CSF exchange between each portion of the CSF system and the surrounding tissue may depend on pathophysiologic conditions that predominate within those compartments. Also, animal studies document lymphatic drainage of CSF via the ethmoidal lymphatics. Lymphatics in the dura of the human ON have also been proposed as a CSF outflow pathway. If such lymphatic drainage systems exist, perhaps microgravity exposure leads to lymph stasis, which could also be a contributing factor for an increase in ON sheath pressures. The unique cul de sac–like anatomic connection between the intracranial SAS and the SAS of the ON may also create an environment that could be impacted by microgravity fluid changes. As noted by Keller et al., it is difficult to explain the hydrodynamics of how cranial CSF that enters the SAS of the ON would change its direction of flow against an intracranial volume gradient to exit the ON sheath. This analysis suggests a rather fragile flow equilibrium within the ON sheath, even in normal subjects. It is self-evident that under normal 1-G physiologic conditions, CSF secretion, flow, and absorption within the ON sheath are balanced. Regardless of the specific origin of CSF production and drainage, long-standing microgravity fluid shifts may bring about alterations in CSF flow dynamics in the intraorbital portion of the SAS, such that CSF enters SAS, but outflow may be slightly impeded. Thus, under prolonged microgravity conditions, CSF in the SAS of the ON may gradually become partially or completely sequestered, producing a type of ON compartment syndrome that may result in varying degrees of disc edema and/or globe flattening, even in the absence of elevated ICP.

A third possible etiology for our findings is ocular hypotony. It is well established that there is an initial spike in intraocular pressure (IOP) on exposure to microgravity followed by a decrease in IOP over a period of days. Unfortunately, no long-term studies of IOP have ever been done in microgravity to document further trends. Head-down bed rest studies suggest that the initial spike in IOP is followed by a leveling or lowering of IOP over a period of days. The initial spike in IOP is thought to occur as a result of choroidal expansion brought about by cephalad fluid shifts. It is hypothesized that the decrease in IOP after the initial spike may be the result of a compensatory decrease in aqueous volume. Although no long-term IOP data exists from space flight, a low IOP on Earth immediately after space missions has been documented as far back as the Apollo Program. Thus, in-flight, postflight, and head-down studies suggest the possibility that a lowering of IOP may occur during extended microgravity exposure. Although the degree of IOP change is unknown, perhaps in some individuals the IOP can decrease to the point where pathologic changes become evident. Ocular hypotony, generally defined as an IOP of <6.5 mmHg, is well-documented to cause disc edema, posterior globe flattening, choroidal folds, and a hyperopic shift very similar to some of our observed changes.

The etiology of the hyperopic shift, more commonly observed during extended microgravity exposure, has been touched on but merits further discussion. In postflight questionnaires completed by approximately 300 NASA astronauts, nearly 50% of astronauts on long-duration ISS missions and 23% on short-duration shuttle missions have complained of degradation in near vision. A postflight refraction change (i.e., hyperopic shift) was documented in 11% and 34% of astronauts after short and long-duration missions, respectively (Table 2). This is more clinically apparent in older astronauts with decreased accommodation. In fact, NASA astronauts over the age of 40 are routinely offered the use of plus lens “Space Anticipation Glasses” preflight should they experience a hyperopic shift during the mission. As noted, this shift is usually reported after weeks or months in space and less often during short flights. The onset of the hyperopic shift seems to be gradual, variable in magnitude, and has been reported to persist in the 1-G environment for months to years after return to Earth. Although 1 long-duration, head-down study documented a decrease in near visual acuity after 4 to 5 days of head-down tilt, another similar study noted no visual changes. Several hypotheses may be offered to explain this hyperopic shift. In theory, variable increases in ICP with resultant increases in subarachnoid pressure could cause corresponding degrees of posterior globe flattening. We have no data to suggest that disc edema and globe

---

**Table 2**

<table>
<thead>
<tr>
<th>Mission Type</th>
<th>Disc Edema</th>
<th>Globe Flattening</th>
</tr>
</thead>
<tbody>
<tr>
<td>Long-duration</td>
<td>24%</td>
<td>16%</td>
</tr>
<tr>
<td>Short-duration</td>
<td>18%</td>
<td>8%</td>
</tr>
</tbody>
</table>

Unfor...
flattening are common findings in astronauts. The normal aging process in those >40 may lead to a progressive shortening of the axial length that could theoretically account for these changes. It would be difficult to explain why this process would be exacerbated by exposure to microgravity. Changes in corneal refractive power after exposure to changes in atmospheric pressure and oxygen partial pressure could be a possible mechanism. However, considerable research has proven that normal, nonrefractive surgery corneas are not subject to refractive changes during exposure to changing environmental conditions. It is also possible, although unlikely, that the fluid shifts within the eye could result in lenticular changes, which may lead to alterations in refractive error.

Choroidal expansion may thus at least partially account for the hyperopic shifts we describe. The spongy, highly vascular choroid is normally approximately 0.3 mm in thickness, is drained by the vortex veins, and is likely sensitive to impeded outflow produced by microgravity. Perhaps not all of the hyperopic shifts we describe were caused by indentation of the globe from an elevated subarachnoid pressure but occurred through a different mechanism. Choroidal volume changes in microgravity may be responsible for the abrupt increase in IOP (within 30 seconds) in orbital and KC-135 parabolic flights as well as head-down studies. Because ocular liquids within the eye are incompressible, the IOP depends on the intraocular fluid volume and the rather rigid elastic properties of the cornea and sclera. Therefore, a bolus of blood introduced into the eye will initially cause a rise in IOP. Although increased episcleral venous pressure and orbital congestion may add to the rise in IOP during microgravity exposure, it would not explain the sudden IOP increase.

This may cause decreased choroidal drainage and lead to a relatively stagnant pooling of blood in the choroid. This process could result in a small but abrupt increase in choroidal volume and may account for the sudden rise in IOP noted during microgravity exposure. The wide spectrum of degree of hyperopic shift would imply that there is some variation in the choroidal anatomy and some are more susceptible to choroidal swelling than others. Choroidal vasculature alterations have been reported in highly myopic eyes but could also exist in the general population. Choroidal engorgement over time may push the macula forward slightly, thus shortening the distance between the macula and the lens. A 0.33-mm anterior displacement at the macula would lead to a 1-D shift toward hyperopia. This choroidal pooling may gradually expand the delicate collagen lamella of the choroid beyond its normal anatomic structural boundaries such that the choroid becomes permanently distended even on return to the 1-G environment and in the presence of normal venous back-pressure. Our case 1, wherein the choroidal folds were well-documented to be present several years after the mission with no evidence of disc edema, may demonstrate this point. Choroidal folds have also been documented to exist for years on Earth in the absence of increased ICP. Therefore, in a space traveler there might not be a fixed distance between the retina and the lens, as there is on Earth. As seen in Table 2, data from postflight questionnaires completed by approximately 300 astronauts after their short- and long-duration space missions showed that approximately 23% of the short-duration and 48% of the long-duration mission astronauts complained of near vision difficulties. It may be that choroidal expansion and presumably a commensurate hyperopic shift may be quite common during space flight and may exist for months to years after return to Earth.

Although a degree of choroidal expansion is likely present in any space traveler some individuals may be anatomically predisposed to the formation of visible choroidal folds. Choroidal folds may be produced by the mechanical indentation of the posterior globe from a rise in subarachnoid pressure. Newell hypothesized that visible choroidal folds may occur as a result of a combination of variable anatomic attachments of the choroid to Bruch’s membrane and some factor that causes congestion in the choriocapillaris. When choroidal expansion occurs and this attachment is not present, the pigment epithelium slips easily over the choriocapillaris, the folds are not produced, and the fundus has a smooth appearance despite choroidal thickening. Alternatively, choroidal congestion combined with adhesions prevents this slipping and leads to the classic striations of choroidal folds. The light lines, seen in ophthalmoscopy, correspond to the crests of the folds where there is compaction of the retinal pigment epithelium. Thus, choroidal expansion may have a different clinical appearance depending on the microanatomy of the individual astronaut. Although prominent choroidal expansion is rather unusual on Earth, our report suggests that it may be common on exposure to extended microgravity. Therefore, the hyperopic shifts observed in these astronauts may not universally result from a rise in ICP or a drop in IOP. However, they may be the consequence of local fluid changes within the eye and orbit brought about by microgravity exposure.

We also report unilateral CWS in 3 astronauts after exposure to extended microgravity. Only one occurred in conjunction with ON edema in that eye. Featherly edged infarctions of the surface of the NFL layer, CWS usually occur in the area of the radial peripapillary capillaries. They are thought to be accumulations of cytoplasmic debris caused by focal obstruction of orthograde and or retrograde axoplasmic transport and they may leave a permanent retinal defect. The fundamental lesion causing a CWS is thought to be precapillary arteriolar closure. Although CWS are nonspecific, they are well known to occur in diabetes mellitus, HIV retinopathy, Purtschers’ retinopathy, high-altitude retinopathy, and hypertensive retinopathy. They are not commonly associated with increased ICP. The etiology of these findings in our astronauts is unknown, but we may assume that these changes are somehow related to cephalad fluid shifts during extended space flight. As noted, local, asymmetric microgravity related changes in CSF flow within the intraorbital portion of the ON may lead to a biochemically altered CSF that may cause a metabolic toxicity to the ON and set the stage for focal arteriolar closure. A similar hypothesis has been pre-
viously proposed as a mechanism for other forms of axoplasmic stasis.

In summary, although a definitive etiology is unknown, we hypothesize that venous congestion in the brain and/or eye, brought about by cephalad fluid shifts and perhaps exacerbated by choroidal volume changes, may be a unifying pathologic mechanism to explain our findings. These findings may occur in conjunction with microgravity-induced CSF flow disturbances within the ON sheath. Regardless of specific etiology, the disc edema, globe flattening, choroidal folds, and hyperopic shifts we report may represent parts of a spectrum of ocular and cerebral response to microgravity. Because all symptoms occurred after long-term exposure to microgravity and the disc edema in 2 astronauts was documented by direct observation on board the spacecraft, it would be extremely unlikely that the effects of takeoff, reentry, or landing were involved. Because detailed preflight and postflight dilated retinal examinations with fundus photography and OCT have only been conducted in NASA astronauts over the last 4 years and all cases we report were largely asymptomatic, this suggests that similar cases may have been missed in the past. Recently, NASA has initiated a protocol to acquire prospective preflight, in-flight, and postflight data on all future astronauts to define the exact origin of these potentially harmful ocular changes. These data would include preflight and postflight MRI, OCT, and LPs when appropriate, as well as preflight, in-flight, and postflight IOP measurement, dilated eye examination, ultrasound imaging, cycloplegic refraction, and fundus photography.

Acknowledgments. The authors thank the Lifetime Surveillance of Astronaut Health Program, NASA Johnson Space Center, for their help with statistical and data management.

References


30. Johnston M, Zakharov A, Koh L, Armstrong D. Subarachnoid injection of Microfil reveals connections between cerebrospi-

Footnotes and Financial Disclosures

Originally received: January 28, 2011.
Final revision: June 17, 2011.
Accepted: June 17, 2011.
Available online: Manuscript no. 2011-155.
1 Department of Ophthalmology, Alaska Native Medical Center, Anchorage, Alaska.
2 Coastal Eye Associates, Webster, Texas.
3 University of Houston, University Eye Institute, Houston, Texas.
4 Department of Diagnostic Imaging and Intervention, University of Texas Health Science Center, Houston, Texas.
5 Department of Ophthalmology, The Methodist Hospital, Houston, Texas.
6 NASA Johnson Space Center, Space Medicine, Houston, Texas.
7 Wyle Integrated Science and Engineering, Houston, Texas.
8 NASA Johnson Space Center, Houston, Texas.
9 German Aerospace Center, Cologne, Germany.
10 Crew Medical Support Office, European Space Agency, Cologne, Germany.

Some activities related to this report were accomplished while under contract paid by the National Aeronautics and Space Administration.

Financial Disclosure(s):
The authors have no proprietary or commercial interest in any of the materials discussed in this article.

Correspondence: Thomas H. Mader, MD, Department of Ophthalmology, Alaska Native Medical Center, 4315 Diplomacy Drive, Anchorage AK 99508. E-mail: tmader@acsalaska.net